Dietary Sodium Restriction Increases the Risk of Misinterpreting Mild Cases of Primary Aldosteronism
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Context: The aldosterone to renin ratio (ARR) is recommended to screen for primary aldosteronism (PA). Objective: To evaluate whether dietary sodium restriction results in misinterpretation of PA screening. Participants: Untreated hypertensives with ARR more than 20 on a high dietary sodium intake (HS) were also evaluated on a low dietary sodium intake (LS) (n = 241). Positive screening for PA was defined as: plasma renin activity (PRA) less than or equal to 1.0 ng/mL · h with serum aldosterone more than or equal to 6 ng/dL. PA was confirmed by a 24-hour urinary aldosterone excretion more than or equal to 12 mcg with urinary sodium more than 200 mmol. Results: Only 33% (79/241) of participants with an ARR more than 20 had a positive PA screen on HS. On LS, 56% (44/79) of these participants no longer met criteria for positive PA screening. When compared with participants with positive PA screening on both diets, participants with a positive screen on HS but negative on LS exhibited a significantly higher PRA on both diets. Remarkably, of the 48/79 participants who had PA confirmed, 52% had negative PA screening on LS. The distinguishing feature of these participants with “discordant” screening results was a larger rise in PRA on LS resulting in normalization of the ARR and higher Caucasian race prevalence. Conclusions: Sodium restriction is recommended in hypertension; however, it can significantly raise PRA, normalize the ARR, and result in false interpretation of PA screening. Milder phenotypes of PA, where PRA is not as suppressed, are most susceptible to dietary sodium influences on renin and ARR. Optimal screening for PA should occur under conditions of HS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lloyd-Jones, D. M., Hong, Y., Labarthe, D., Mozaffarian, D., Appel, L. J., Van Horn, L., Greenlund, K., Daniels, S., Nichol, G., Tomaselli, G. F., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192703 · Cited by 4,750
Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4061 · Cited by 2,925 · cited 8×
“We used this ARR cutoff because it is highly sensitive and therefore ensured that we would not miss potential cases of PA among our population of mild hypertensives on a high dietary sodium balance (6).”
BackgroundMethodInfluentialSchwartz, G. L., & Turner, S. T. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.041780 · Cited by 221
Hanslik, G., Wallaschofski, H., Dietz, A., Riester, A., Reincke, M., Allolio, B., Lang, K., Quack, I., Rump, L. C., Willenberg, H. S., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0450 · Cited by 155 · cited 1×
“syndrome, and cardiovascular mortality (4, 5).”
Resistant Hypertension: A Review of Diagnosis and Management
Vongpatanasin, W. (2014) · JAMA · doi:10.1001/jama.2014.5180 · Cited by 146
Pimenta, E., Stowasser, M., Gordon, R. D., Harding, S. M., Batlouni, M., Zhang, B., Oparil, S., & Calhoun, D. A. (2013) · Chest · doi:10.1378/chest.12-0802 · Cited by 69 · cited 1×
“Study procedures included measurement of morning plasma renin activity (PRA) and serum aldosterone, and serum and urinary sodium and potassium, as we have described before (13).”
Method
Cited by
Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., & Vaidya, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30367-4 · Cited by 677
Self-citationThe Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study
Brown, J. M., Siddiqui, M., Calhoun, D. A., Carey, R. M., Hopkins, P. N., Williams, G. H., & Vaidya, A. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0065 · Cited by 649
Self-citationPrimary Aldosteronism: An Endocrine Society Clinical Practice Guideline
Adler, G. K., Stowasser, M., Correa, R. R., Khan, N., Kline, G., McGowan, M. J., Mulatero, P., Murad, M. H., Touyz, R. M., Vaidya, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf284 · Cited by 355
Self-citationMulatero, P., Monticone, S., Deinum, J., Amar, L., Prejbisz, A., Zennaro, M.-C., Beuschlein, F., Rossi, G. P., Nishikawa, T., Morganti, A., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002510 · Cited by 317
Vaidya, A., Mulatero, P., Baudrand, R., & Adler, G. K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00139 · Cited by 299
Self-citationThe Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study
Brown, J. M., Robinson-Cohen, C., Luque-Fernandez, M. A., Allison, M. A., Baudrand, R., Ix, J. H., Kestenbaum, B., de Boer, I. H., & Vaidya, A. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0882 · Cited by 221
“Studies in mildly hypertensive populations have shown that 3% to 20% of persons with stage 1 hypertension show overt biochemical confirmation for PA on salt suppression, fludrocortisone, or captopril suppression tests (44–46) and that the degree of renin suppression predicts the severity of PA (44).”
Self-citationPrimary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment
Hundemer, G. L. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1185-x · Cited by 27
Metadata
- Authors
- Baudrand, R., Guarda, F. J., Torrey, J., Williams, G., & Vaidya, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-07-18
- Volume
- 101
- Issue
- 11
- Pages
- 3989-3996
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2484432461
- Cited by
- 78
- References
- 6
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.